Magdalena Biosciences, the Jaguar Health–Filament Health JV, has begun preclinical tests of coca-based appetite suppressants.

Magdalena Biosciences, a joint venture between Jaguar Health, Inc. (NASDAQ: JAGX) and Filament Health Corp. (OTC: FLHLF), has initiated a preclinical study evaluating whole-leaf coca extract as a potential treatment for appetite suppression and weight management.

The study represents an early step in the companies’ efforts to develop plant-derived pharmaceutical therapies and explore new approaches to metabolic health.

Preclinical study evaluates coca extract for weight management

The one-month preclinical study is being conducted in Alberta, Canada and will examine the effects of coca extract in a mouse model. Researchers will analyze whether the botanical compound can help regulate appetite and support weight management, particularly following discontinuation of GLP-1 medications.

The research aims to determine whether coca-derived compounds may influence metabolic pathways involved in hunger and energy balance.

Joint venture focused on plant-based pharmaceutical development

Magdalena Biosciences was formed in 2023 through a collaboration between Jaguar Health and Filament Health. The venture focuses on developing pharmaceutical products derived from plant-based compounds for mental health, neurological, and metabolic conditions.

The partnership combines Jaguar Health’s botanical research capabilities with Filament Health’s drug development platform to advance plant-derived therapies through the pharmaceutical pipeline.

The project also received early funding support from the investment group One Small Planet.

Coca extract sourced under regulated guidelines

The coca leaf material used in the study was supplied by Empresa Nacional de la Coca (ENACO), Peru’s state-owned coca authority responsible for regulating legal coca production.

Researchers are evaluating the extract under U.S. Food and Drug Administration botanical drug development guidelines. The material was also certified under the Nagoya Protocol, which governs access to biological resources and ensures equitable use of biodiversity.

Future research may explore neurological applications

While the initial study focuses on appetite control and weight management, Magdalena Biosciences plans to explore additional therapeutic applications for coca-derived compounds.

Future research programs may investigate potential treatments for neurological and psychiatric conditions, including attention-deficit/hyperactivity disorder (ADHD) and other central nervous system disorders.

Investor perspective

For investors, the program represents an early-stage expansion of the botanical drug development pipeline for Jaguar Health and Filament Health. Plant-derived pharmaceutical compounds are gaining attention as researchers explore alternative therapies for metabolic and neurological disorders.

However, the project remains in the preclinical stage, meaning further research, clinical trials, and regulatory review will be required before any potential commercial use.

Bottom line

Magdalena Biosciences has launched a preclinical study evaluating coca extract as a potential therapy for appetite suppression and weight management. The initiative highlights ongoing collaboration between Jaguar Health and Filament Health as they explore plant-based pharmaceutical treatments targeting metabolic and neurological conditions.